Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS085093)
Angelman Syndrome Foundation
National Institutes of Health (P30CA023168)
National Cancer Institute (Z01-BC006161)
Text and Data Mining valid from 2018-08-17
Received: 14 March 2018
Accepted: 6 August 2018
First Online: 17 August 2018
Ethics approval and consent to participate
: Not applicable
: NCI has provided their consent to publish.
: Not applicable to authors except MC, who is on the Board of Directors and an investor in Gibson Oncology, Inc., which has licensed indenoisoquinoline intellectual property owned by Purdue University. Neither Gibson Oncology nor any other commercial company sponsored or provided other direct financial support to the author or his laboratory for the research reported in this article.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.